The 30 references in paper V. Petrov I., S. Nedogoda V., M. Frolov Yu., A. Salasyuk S., I. Barykina N., V. Smirnova O., V. Khripaeva Yu., В. Петров И., С. Недогода В., М. Фролов Ю., А. Саласюк С., И. Барыкина Н., В. Смирнова О., В. Хрипаева Ю. (2016) “Сравнительный клинико-экономический анализ интенсификации терапии базальным инсулином или дапаглифлозином у пациентов с неконтролируемым сахарным диабетом 2-го типа // COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN” / spz:neicon:pharmacoeconomics:y:2016:i:1:p:58-68

1
Algorithms specialized medical care to patients with diabetes mellitus. Ed. II Grandfathers MV Shestakova (7th edition) [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. I.I. Dedova, M.V. Shestakovoi (7-i vypusk) (In Russian)]. Sakharnyi diabet. 2015; 18 (1S): 1-112.
(check this in PDF content)
2
Dedov I.I. et al. Sakharnyi diabet. 2010; 1.
(check this in PDF content)
3
Dedov I.I. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2012; 1.
(check this in PDF content)
4
Dedov I.I., Shestakova M.V., Vikulova O.K. Sakharnyi diabet. 2015; 18 (3): 5-22.
(check this in PDF content)
5
Dedov I.I., Shestakova M.V. Sakharnyi diabet. 2013; special issue: 5-6, 10-26, 32-34.
(check this in PDF content)
6
Kalashnikova M.F., Suntsov Yu.I., Belousov D.Yu., Kantemirova M.A. Sakharnyi diabet. 2014 ; 3: 5-16.
(check this in PDF content)
7
Petrov V.I., Sabanov A.V. undamentals of pharmacoepidemiology. Selected lectures of scientists Volgmu with aspects of evidencebased medicine [Osnovy farmakoepidemiologii Izbrannye lektsii uchenykh VolGMU s aspektami dokazatel'noi meditsiny (In Russian)]. Volgograd. 2008; 63-65.
(check this in PDF content)
8
Serdyukova D.M. Impact cost of the disease on the optimal choice of pharmacotherapy for type 2 diabetes. PhD diss. [Vliyanie stoimosti bolezni na optimal'nyi vybor farmakoterapii sakharnogo diabeta 2 tipa. Avtoreferat dis. ... kand. med. nauk (In Russian)]. Volgograd. 2015; 24 s.
(check this in PDF content)
9
Suntsov Yu.I. Sakharnyi diabet. 2013; 2S.
(check this in PDF content)
10
Suntsov Yu.I., Dedov I.I. Sakharnyi diabet. 2005; 2: 2-6.
(check this in PDF content)
11
Shestakova M.V., Khalimov Yu.Sh., Novikov V.I. Klin farmakol terapiya. 2009; 18 (2): 92-96.
(check this in PDF content)
12
Yagudina R.I., Kulikov A.Yu., Serpik V.G. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 4: 10-13.
(check this in PDF content)
13
Clarke P., Gray A., Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Medical Decision Making. 2002; 22 (4): 340-349.
(check this in PDF content)
14
Currie C.J. et al. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value in health. 2005; 8 (5): 581-590.
(check this in PDF content)
15
DeFronzo R.A., Eldor R., Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care. 2013; 36 (2): 127-138.
(check this in PDF content)
16
Del Prato S. et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes, Obesity and Metabolism. 2015; 17 (6): 581-590.
(check this in PDF content)
17
Garber A. et al. Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Diabetes, Obesity and Metabolism. 2006; 8 (2): 156-163.
(check this in PDF content)
18
Gerstein H.C. et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. The New England journal of medicine. 2012; 367 (4): 319-328.
(check this in PDF content)
19
Grandy S. et al. Health-related quality of life (EQ-5D) among type 2 diabetes mellitus patients treated with dapagliflozin over 2 years. International journal of clinical practice. 2014; 68 (4): 486-494.
(check this in PDF content)
20
Guariguata L. et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes research and clinical practice. 2014; 103 (2): 137-149.
(check this in PDF content)
21
IMS Health (2007): Medical Ambition II – Supplement: Extension to newly diagnosed patients, Basel Switzerland; In: Novo Nordisk S/A (2007) Changing Diabetes Barometer First Report, 63.
(check this in PDF content)
22
International Diabetes Federation. IDF Diabetes, 7 ed. Brussels, Belgium: International Diabetes Federation, 2015. http://www.diabetesatlas.org. Accessed: 17.01.16.
(check this in PDF content)
23
Matthaei S. et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38 (3): 365-372.
(check this in PDF content)
24
Oxford Outcomes. Societal and patient utilities for type 2 diabetes health states: A Canadian, Australian and United Kingdom perspective, Final Report, August 12, 2011.
(check this in PDF content)
25
Pfohl M. et al. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study. Vascular health and risk management. 2015; 11: 569.
(check this in PDF content)
26
Ptaszynska A. et al. Effects of dapagliflozin on cardiovascular risk factors. Postgraduate medicine. 2013; 125 (3): 181-189.
(check this in PDF content)
27
Rao A.D. et al. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or allcause mortality? A meta-analysis of observational studies. Diabetes care. 2008; 31 (8): 1672-1678.
(check this in PDF content)
28
Russell-Jones D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia. 2009; 52 (10): 2046-2055.
(check this in PDF content)
29
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854-865.
(check this in PDF content)
30
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853. Сведения об авторах:
(check this in PDF content)